Literature DB >> 18936455

Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction.

Peter C Austin1, Jack V Tu, Dennis T Ko, David A Alter.   

Abstract

BACKGROUND: In an accompanying article, we report moderate between-hospital variation in the postdischarge use of beta-blockers, angiotensin-modifying drugs and statins by elderly patients who had been admitted to hospital with acute myocardial infarction. Our objective was to identify the characteristics of patients, physicians, hospitals and communities associated with differences in the use of these medications after discharge.
METHODS: For this retrospective, population-based cohort study, we used linked administrative databases. We examined data for all patients aged 65 years or older who were discharged from hospital in 2005/06 with a diagnosis of myocardial infarction. We determined the effect of patient, physician, hospital and community characteristics on the rate of postdischarge medication use.
RESULTS: Increasing patient age was associated with lower postdischarge use of medications. The odds ratios (ORs) for a 1-year increase in age were 0.98 (95% confidence interval [CI] 0.97-0.99) for beta-blockers, 0.97 (95% CI 0.97-0.98) for angiotensin-converting-enzyme inhibitors and angiotensin-receptor blockers and 0.94 (95% CI 0.93-0.95) for statins. Having a general or family practitioner, a general internist or a physician of another specialty as the attending physician, relative to having a cardiologist, was associated with lower postdischarge use of beta-blockers, angiotensin-modifying agents and statins (ORs ranging from 0.46 to 0.82). Having an attending physician with 29 or more years experience, relative to having a physician who had graduated within the past 15 years, was associated with lower use of beta-blockers (OR 0.71, 95% CI 0.60-0.84) and statins (OR 0.81, 95% CI 0.67-0.97).
INTERPRETATION: Patients who received care from noncardiologists and physicians with at least 29 years of experience had substantially lower use of evidence-based drug therapies after discharge. Dissemination strategies should be devised to improve the prescribing of evidence-based medications by these physicians.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936455      PMCID: PMC2565714          DOI: 10.1503/cmaj.080295

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  19 in total

1.  The effect of physicians' training on prescribing beta-blockers for secondary prevention of myocardial infarction in the elderly.

Authors:  Adrian R Levy; Robyn M Tamblyn; Peter J Mcleod; David Fitchett; Michal Abrahamowicz
Journal:  Ann Epidemiol       Date:  2002-02       Impact factor: 3.797

2.  The use of angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction in community hospitals. Michigan State University Inter-Institutional Collaborative Heart (MICH) Study Group.

Authors:  F C Dwamena; H El-Tamimi; R E Watson; J Kroll; A D Stein; A McLane; M Holmes-Rovner; B McIntosh; J Kupersmith
Journal:  Clin Cardiol       Date:  2000-05       Impact factor: 2.882

3.  Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario.

Authors:  P A Rochon; G M Anderson; J V Tu; J P Clark; J H Gurwitz; J P Szalai; P Lau
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

4.  Physician characteristics and the initiation of beta-adrenergic blocking agent therapy after acute myocardial infarction in a managed care population.

Authors:  S N Fehrenbach; D S Budnitz; J A Gazmararian; H M Krumholz
Journal:  Am J Manag Care       Date:  2001-07       Impact factor: 2.229

5.  Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996.

Authors:  J V Tu; C D Naylor; P Austin
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

6.  Development and validation of the Ontario acute myocardial infarction mortality prediction rules.

Authors:  J V Tu; P C Austin; R Walld; L Roos; J Agras; K M McDonald
Journal:  J Am Coll Cardiol       Date:  2001-03-15       Impact factor: 24.094

7.  Relationship between annual volume of patients treated by admitting physician and mortality after acute myocardial infarction.

Authors:  J V Tu; P C Austin; B T Chan
Journal:  JAMA       Date:  2001-06-27       Impact factor: 56.272

8.  An introduction to multilevel regression models.

Authors:  P C Austin; V Goel; C van Walraven
Journal:  Can J Public Health       Date:  2001 Mar-Apr

9.  A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario.

Authors:  Peter C Austin; Paul A Daly; Jack V Tu
Journal:  Am Heart J       Date:  2002-08       Impact factor: 4.749

10.  Comparing hierarchical modeling with traditional logistic regression analysis among patients hospitalized with acute myocardial infarction: should we be analyzing cardiovascular outcomes data differently?

Authors:  Peter C Austin; Jack V Tu; David A Alter
Journal:  Am Heart J       Date:  2003-01       Impact factor: 4.749

View more
  12 in total

1.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

Review 2.  Myocardial infarction and quality of care.

Authors:  Jersey Chen; Sharon-Lise T Normand
Journal:  CMAJ       Date:  2008-10-21       Impact factor: 8.262

Review 3.  Resource Effective Strategies to Prevent and Treat Cardiovascular Disease.

Authors:  J D Schwalm; Martin McKee; Mark D Huffman; Salim Yusuf
Journal:  Circulation       Date:  2016-02-23       Impact factor: 29.690

4.  FRAX and ethnicity.

Authors:  J A Kanis; C Cooper; B Dawson-Hughes; N C Harvey; H Johansson; M Lorentzon; E V McCloskey; J-Y Reginster; R Rizzoli
Journal:  Osteoporos Int       Date:  2020-09-04       Impact factor: 4.507

5.  Closing the gap in postfracture care at the population level: a randomized controlled trial.

Authors:  William D Leslie; Lisa LaBine; Penny Klassen; Darlene Dreilich; Patricia A Caetano
Journal:  CMAJ       Date:  2011-12-19       Impact factor: 8.262

6.  Physician and patient influences on provider performance: β-blockers in postmyocardial infarction management in the MI-Plus study.

Authors:  Ellen Funkhouser; Thomas K Houston; Deborah A Levine; Joshua Richman; Jeroan J Allison; Catarina I Kiefe
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-12-07

7.  Secondary prevention medication after myocardial infarction: persistence in elderly people over the course of 1 year.

Authors:  Saba Al-Khadra; Christa Meisinger; Ute Amann; Rolf Holle; Bernhard Kuch; Hildegard Seidl; Inge Kirchberger
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

8.  Delayed educational reminders for long-term medication adherence in ST-elevation myocardial infarction (DERLA-STEMI): protocol for a pragmatic, cluster-randomized controlled trial.

Authors:  Noah M Ivers; Jon-David Schwalm; Jeremy M Grimshaw; Holly Witteman; Monica Taljaard; Merrick Zwarenstein; Madhu K Natarajan
Journal:  Implement Sci       Date:  2012-06-09       Impact factor: 7.327

9.  Does the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort study.

Authors:  Mhd Wasem Alsabbagh; Dean Eurich; Lisa M Lix; Thomas W Wilson; David F Blackburn
Journal:  BMC Med Res Methodol       Date:  2017-04-20       Impact factor: 4.615

10.  Impact of Age, Multimorbidity and Frailty on the Prescription of Preventive Antiplatelet Therapy in Older Population.

Authors:  Caroline Laborde; Jérémy Barben; Anca-Maria Mihai; Valentine Nuss; Jérémie Vovelle; Philippe d'Athis; Pierre Jouanny; Alain Putot; Patrick Manckoundia
Journal:  Int J Environ Res Public Health       Date:  2020-06-24       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.